Another Alzheimer's Setback As Roche And Lilly Drugs Fail
Fresh Disappointment For Amyloid Hypothesis
As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.
You may also be interested in...
Any product would be mostly covered by Medicare, but because the potential patient population will likely be 'substantial,' payers will likely 'closely scrutinize' these drugs, Duke Margolis white paper observes.
Japanese firm sets stage to acquire US bioventure after it raises stake just ahead of key readout for lead asset.
US FDA approval of the Alzheimer's drug may be uncertain, but Biogen will be investing substantially behind a commercial buildout this year.